Siemens Healthineers: Imaging Powers Ahead as Diagnostics Sinks — and a €230m Buyback Arrives
31.05.2026 - 16:22:35 | boerse-global.de
Siemens Healthineers is navigating a starkly divided reality. Its Imaging division is sprinting, with the latest molecular imaging systems on display at the SNMMI conference in Los Angeles and a blockbuster 22.4% adjusted EBIT margin in the second quarter. But the Diagnostics business remains a millstone, posting a 6.5% comparable revenue decline and a margin that barely scraped 0.9%. Against that backdrop, the company has fired a fresh capital-allocation signal: a share buyback programme worth up to €230 million, set to begin in June and run until January 2027.
The timing of the buyback is no accident. The stock closed Friday at €34.91, a mere 0.06% gain on the day and a full 30% below its 52-week high of €49.86. Since the start of the year, shares have lost 21.44% of their value and now sit just 5% above the 52-week trough of €33.34. The 50-day moving average at €35.86 offers an immediate overhead test, while the 200-day average at €42.33 — nearly 18% above the current price — underscores how steep the slide has become.
The second-quarter results, published in May, lay bare the split. Imaging delivered comparable revenue growth of 6.1% on a base of nearly €3 billion, fuelled by magnetic resonance and the very molecular imaging systems now on show in Los Angeles. Precision Therapy followed with 4.7% growth and a 13.3% margin. Diagnostics, by contrast, suffered a 6.5% comparable drop, which management attributes to structural changes in the Chinese market — a recurring headache that has already forced the company to trim its guidance.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
For the full fiscal year 2026, Siemens Healthineers now expects comparable revenue growth of 4.5% to 5.0% and adjusted earnings per share between €2.20 and €2.30. The narrowing of that range has made investors wary, and the Diagnostics overhang is the primary reason. The buyback, while modest relative to a market cap above €30 billion, is intended as a tangible signal of management’s confidence in the overall business and its ability to generate cash.
A string of investor events in June, including a roadshow and the BNP Paribas CEO conference in Paris, offers the next opportunity for executives to address margins, capital allocation, and the China diagnostics strategy directly. Meanwhile, the SNMMI conference serves as a operational counterpoint: here, the company is showcasing its new PET/CT, SPECT/CT and PET/MR systems combined with digital workflow and radiopharma solutions. The Imaging division is the stability anchor the group needs right now, and the product offensive aims to keep it that way.
From a technical perspective, the €34.91 level leaves limited downside before the 52-week low comes into play. The 50-day moving average sits just above at €35.86, and a close above that would be the first step toward regaining the broken 200-day line. However, the macro calendar offers little specific catalyst for med-tech names — Germany’s May inflation rate came in at 2.6%, and the forthcoming PMI readings for industry and services will set the tone for European equities in general without directly altering the Siemens Healthineers story.
The buyback is a concrete factor for the months ahead. Whether it acts as a stabiliser or simply masks the ongoing Diagnostics concern will become clearer once the next quarterly numbers are published — or if the company delivers any material deviation from its revised outlook. For now, investors are left weighing the strength of Imaging against the persistent drag from Diagnostics, with a €230 million vote of confidence from management in the balance.
Ad
Siemens Healthineers Stock: New Analysis - 31 May
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis Siemens Aktien ein!
FĂĽr. Immer. Kostenlos.
